Unexpected Finding: Pancreatic Cells May Generate a Compound Resembling Ozempic

Health
By Newsroom,  published 25 September 2025 at 10h01, updated on 25 September 2025 at 10h01.
Health

ADN

Researchers have made a striking discovery indicating that certain pancreatic cells are capable of generating a compound akin to Ozempic, a medication commonly prescribed for diabetes and weight management, potentially opening new avenues in medical treatment.

TL;DR

  • Pancreatic alpha cells can produce GLP-1, aiding diabetes care.
  • Discovery may reduce reliance on expensive Ozempic injections.
  • Further research needed before new therapies reach humans.

    • Unexpected Findings in the Pancreas

    A recent breakthrough from researchers at Duke University has shifted scientific understanding of how the pancreas contributes to the management of both diabetes and obesity. While most eyes have been on rising global rates of obesity—largely fuelled by increased consumption of ultra-processed foods and sedentary lifestyles—this new study, published in Science Advances, uncovers a surprising function in pancreatic alpha cells. Traditionally, these cells have been recognized solely for producing glucagon, a hormone responsible for raising blood sugar levels. Now, evidence reveals they can also synthesize GLP-1, a hormone instrumental in stimulating insulin production and moderating digestion.

    Challenging the Status Quo in Diabetes Treatment

    The rush to find effective treatments has led many to inject medications like Ozempic, which mimics GLP-1’s effects. Though widely prescribed for type 2 diabetes—and sometimes used off-label for weight loss despite a lack of FDA approval—sémaglutide-based treatments come with considerable drawbacks: high cost, side effects, and limited accessibility. The latest findings may offer a path to sidestep some of these issues.

    Researchers observed that when the enzyme PC2 is inhibited within alpha cells (shifting preference toward PC1/3), those same cells increase their natural production of GLP-1. Remarkably, this “program switch” was documented not just in mouse models but also across various samples of human tissue.

    Therapeutic Horizons: Hope and Caution

    Through advanced mass spectrometry, scientists quantified active GLP-1 levels generated by these reprogrammed cells after food intake. Their results showed that endogenous GLP-1 could amplify insulin secretion from beta cells and help regulate blood sugar more efficiently—potentially mitigating glucagon’s glucose-raising effect.

    This development points toward promising future applications:

  • Encouraging patients’ own bodies to boost GLP-1 naturally;
  • Paving the way for reduced reliance on costly injectable drugs;
  • Targeting specific enzymes pharmacologically to fine-tune the process.

    • However, experts urge caution. Manipulating this hormonal balance is fraught with challenges—including ensuring safety from hypoglycemia or other metabolic disruptions.

    The Road Ahead: Possibilities and Uncertainties

    At present, these discoveries remain largely confined to laboratory settings. Most experiments have involved tissue samples or animal models, leaving several critical questions about human application unanswered. Before any real-world shift in therapy emerges, researchers must establish reliable methods for measuring endogenous GLP-1 and safely triggering the cellular switch. Still, amid measured optimism and inevitable scientific hesitance, this revelation about the pancreas hints at new possibilities—not only for managing diabetes but potentially addressing obesity itself down the line.